tag:www.gov.uk,2005:/drug-safety-update Drug Safety Update about Ear, nose and throat 2024-04-29T16:03:09+01:00 HM Government tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-march-2024 2024-04-29T16:03:09+01:00 Letters and medicine recalls sent to healthcare professionals in March 2024 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-february-2024 2024-03-27T11:53:02+00:00 Letters and medicine recalls sent to healthcare professionals in February 2024 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. tag:www.gov.uk,2005:/drug-safety-update/pseudoephedrine-very-rare-risk-of-posterior-reversible-encephalopathy-syndrome-pres-and-reversible-cerebral-vasoconstriction-syndrome-rcvs 2024-02-20T11:01:34+00:00 Pseudoephedrine: very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) There have been very rare reports of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with pseudoephedrine. tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-january-2024 2024-02-20T11:01:30+00:00 Letters and medicine recalls sent to healthcare professionals in January 2024 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. tag:www.gov.uk,2005:/drug-safety-update/codeine-linctus-public-consultation-on-the-proposal-to-reclassify-to-a-prescription-only-medicine 2023-07-24T13:59:27+01:00 Codeine linctus: public consultation on the proposal to reclassify to a prescription-only medicine We have launched a public consultation on the proposal to reclassify codeine linctus to a prescription-only medicine. tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-april-2023 2023-05-25T10:53:17+01:00 Letters and medicine recalls sent to healthcare professionals in April 2023 Recent MHRA National Patient Safety Alerts to remove from service Philips Health Systems V60 and V60 Plus ventilators and to recall Emerade adrenaline auto-injectors from patients, pharmacies and wholesalers. We also provide� tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-march-2022 2022-04-19T14:27:17+01:00 Letters and medicine recalls sent to healthcare professionals in March 2022 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. Includes a recent recall of Accuretic (quinapril hydrochloride and hydrochlorothiazide). tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-october-2021 2021-11-16T14:22:16+00:00 Letters and medicine recalls sent to healthcare professionals in October 2021 A summary of recent letters, medicine recalls and notifications sent to healthcare professionals. tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-july-2019 2019-08-19T15:47:40+01:00 Letters and drug alerts sent to healthcare professionals in July 2019 Letters were sent about Oncaspar� (pegaspargase), Ketalar (ketamine) injection, and Elmiron (pentosan polysulfate sodium). A recall was issued for several medicines taken out of the regulated medicines supply chain, includin� tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-june-2019 2019-07-17T13:34:54+01:00 Letters and drug alerts sent to healthcare professionals in June 2019 Letters were sent about Myocrisin (sodium aurothiomalate), Cerliponase alfa (Brineura�), Darzalex�(daratumumab), retinoids�, and febuxostat (Adenuric). A recall alert was issued for medicines that were taken out of the regul� tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-march-2019 2019-04-16T15:53:23+01:00 Letters and drug alerts sent to healthcare professionals in March 2019 Letters were sent about Xeljanz� (tofacitinib), ranitidine, Nulojix (belatacept), fluoroquinolone antibiotics, Genvoya�, Stribild�, Tybost, and belimumab (Benlysta�). Drug alerts were issued about Accord losartan potassium c� tag:www.gov.uk,2005:/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects 2019-03-21T11:50:07+00:00 Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics. Fluoroquinolone treatment should be discont� tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-february-2019 2019-03-21T11:49:28+00:00 Letters and drug alerts sent to healthcare professionals in February 2019 Letters were sent about Vyxeos (cytarabine, daunorubicin) and Ozurdex 700 micrograms intravitreal implant (dexamethasone). Alerts were issued about irbesartan, amoxicillin, atropine sulfate, and paracetamol infusion. tag:www.gov.uk,2005:/drug-safety-update/medicines-taken-during-pregnancy-please-report-suspected-adverse-drug-reactions-including-in-the-baby-or-child-on-a-yellow-card 2018-07-17T14:35:39+01:00 Medicines taken during pregnancy: please report suspected adverse drug reactions, including in the baby or child, on a Yellow Card Report to the Yellow Card Scheme suspected adverse reactions associated with medicines taken during pregnancy experienced by women or the baby or child. Obstetricians and midwives have a particularly important role in provid� tag:www.gov.uk,2005:/drug-safety-update/medical-device-alerts-issued-in-february-2018 2018-03-08T14:21:11+00:00 Medical Device Alerts issued in February 2018 Alerts were recently issued about RUSCH rectal/pharyngeal temperature sensors and Aquilon nebulisers. tag:www.gov.uk,2005:/drug-safety-update/miconazole-daktarin-over-the-counter-oral-gel-contraindicated-in-patients-taking-warfarin 2017-09-26T16:57:40+01:00 Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin Patients taking warfarin should not use over-the-counter miconazole oral gel (Daktarin). If you plan to prescribe miconazole oral gel in a patient on warfarin, you should closely monitor them and advise that if they experien� tag:www.gov.uk,2005:/drug-safety-update/denosumab-prolia-xgeva-reports-of-osteonecrosis-of-the-external-auditory-canal 2017-06-21T09:54:51+01:00 Denosumab (Prolia, Xgeva�): reports of osteonecrosis of the external auditory canal Denosumab is associated with a risk of osteonecrosis of the jaw, osteonecrosis of the external auditory canal has also been reported with denosumab. tag:www.gov.uk,2005:/drug-safety-update/pseudoephedrine-and-ephedrine-regular-review-of-minimising-risk-of-misuse-in-the-uk 2017-06-21T09:53:48+01:00 Pseudoephedrine and ephedrine: regular review of minimising risk of misuse in the UK Sales restrictions introduced in 2008 continue to be successful in managing the risk of misuse of pseudoephedrine and ephedrine. tag:www.gov.uk,2005:/drug-safety-update/bisphosphonates-very-rare-reports-of-osteonecrosis-of-the-external-auditory-canal 2015-12-14T16:18:16+00:00 Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal Osteonecrosis of the external auditory canal has been reported very rarely (fewer than 1 in 10 000 patients) with bisphosphonates, mainly in association with long-term therapy (2 years or longer). tag:www.gov.uk,2005:/drug-safety-update/codeine-for-analgesia-restricted-use-in-children-because-of-reports-of-morphine-toxicity 2014-12-11T14:35:09+00:00 Codeine for analgesia: restricted use in children because of reports of morphine toxicity Codeine should only be used to relieve acute moderate pain in children older than 12 years and only if it cannot be relieved by other painkillers such as paracetamol or ibuprofen alone. Furthermore, a significant risk of se� tag:www.gov.uk,2005:/drug-safety-update/codeine-containing-pain-relief-in-children 2014-12-11T14:34:06+00:00 Codeine-containing pain relief in children Safety review initiated following post-surgical fatalities in ultra-rapid metabolisers tag:www.gov.uk,2005:/drug-safety-update/codeine-containing-liquid-over-the-counter-medicines 2014-12-11T14:29:42+00:00 Codeine-containing liquid over-the-counter medicines. Should not be used for cough under 18 years tag:www.gov.uk,2005:/drug-safety-update/inhaled-and-intranasal-corticosteroids 2014-12-11T14:29:32+00:00 Inhaled and intranasal corticosteroids Risk of psychological and behavioural side effects. tag:www.gov.uk,2005:/drug-safety-update/pseudoephedrine-and-ephedrine-nasal-decongestants 2014-12-11T14:27:17+00:00 Pseudoephedrine and ephedrine: nasal decongestants How to reduce risk of illicit use. tag:www.gov.uk,2005:/drug-safety-update/the-black-triangle-scheme-or 2014-12-11T14:26:43+00:00 The Black Triangle Scheme (� or �*) Continued monitoring of medicines with a black triangle status. tag:www.gov.uk,2005:/drug-safety-update/ecoflac-infusion-solutions-risk-of-air-embolism 2014-12-11T14:24:01+00:00 Ecoflac infusion solutions: risk of air embolism To avoid the risk of air embolism, these products should not be infused under pressure. tag:www.gov.uk,2005:/drug-safety-update/corticosteroids-early-psychiatric-side-effects 2014-12-11T14:23:40+00:00 Corticosteroids: early psychiatric side-effects Risk of early psychiatric side-effects is one of several important safety issues for healthcare professionals to discuss with patients and carers, who should seek urgent medical advice in the event of any worrying symptoms.